Cardiff Oncology ‘highly encouraged’ by onvansertib data presented at ASCO

Cardiff Oncology (CRDF) announced “positive” data from an investigator-initiated Phase 1b clinical trial evaluating onvansertib in combination with paclitaxel in patients with metastatic triple-negative breast cancer at the American Society of Clinical Oncology Annual Meeting, taking place from May 30-June 3 in Chicago, Illinois. “Triple-negative breast cancer is among the most aggressive subtypes of breast cancer, and represents a significant unmet medical need for women worldwide. This underscores the urgency to develop novel therapies with enhanced efficacy and improved tolerability for patients with mTNBC,” said Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology. “We are highly encouraged by the robust efficacy signal and the tolerable safety profile observed with onvansertib plus paclitaxel in patients with mTNBC. The majority of the patients were heavily pretreated and three of the four objective responses were observed in patients that had prior exposure to paclitaxel. Additionally, we observed a dose-response relationship, with the highest dose of onvansertib resulting in a 40% objective response rate. These findings offer clinical validation of previously reported preclinical data demonstrating synergy between onvansertib and paclitaxel. Overall, we are excited with these results and remain focused on developing onvansertib across multiple cancer types.” Collectively, this clinical data further supports the potential exploration of the combination of onvansertib plus paclitaxel for the treatment of mTNBC, the company added.